Dissemin is shutting down on January 1st, 2025

Published in

Nature Research, Nature Communications, 1(12), 2021

DOI: 10.1038/s41467-021-23472-7

Links

Tools

Export citation

Search in Google Scholar

A new molecular classification to drive precision treatment strategies in primary Sjögren’s syndrome

Journal article published in 2021 by Perrine Soret, Torsten Witte, Michael Zauner, Barbara Vigone, Enrique de Ramon, Aleksandra Zuber, Donatienne Wynar, Carlos Vasconcelos, Ana Tavares, Georg Stummvoll, T. Witte, Laura Xuereb, Silvia Thiel, Nieves Varela, Elena Trombetta and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Red circle
Postprint: archiving forbidden
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

AbstractThere is currently no approved treatment for primary Sjögren’s syndrome, a disease that primarily affects adult women. The difficulty in developing effective therapies is -in part- because of the heterogeneity in the clinical manifestation and pathophysiology of the disease. Finding common molecular signatures among patient subgroups could improve our understanding of disease etiology, and facilitate the development of targeted therapeutics. Here, we report, in a cross-sectional cohort, a molecular classification scheme for Sjögren’s syndrome patients based on the multi-omic profiling of whole blood samples from a European cohort of over 300 patients, and a similar number of age and gender-matched healthy volunteers. Using transcriptomic, genomic, epigenetic, cytokine expression and flow cytometry data, combined with clinical parameters, we identify four groups of patients with distinct patterns of immune dysregulation. The biomarkers we identify can be used by machine learning classifiers to sort future patients into subgroups, allowing the re-evaluation of response to treatments in clinical trials.